FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898049158> ?p ?o ?g. }

• W2898049158 endingPage "S50" @default.
• W2898049158 startingPage "S49" @default.
• W2898049158 abstract "Results from COG ACNS0122 utilizing a combination of chemotherapy and craniospinal irradiation (CSI) demonstrated excellent 5-year outcomes for non-germinomatous germ cell tumors (NGGCTs). The majority of failures for non-metastatic NGGCTs were local on that trial. COG ACNS 1123 tested the efficacy of reduced dose and field radiation therapy (RT) for non-metastatic patients who achieved a complete (CR) or partial response (PR) to chemotherapy. Here, we evaluate the quality of RT and patterns of failure for NGGCT patients eligible for reduced dose and field radiation therapy on this prospective phase II trial. Patients with localized NGGCT received alternating cycles of carboplatin/etoposide and ifosfamide/etoposide (6 total) followed by response evaluation. Those who became tumor marker negative and achieved radiological CR or PR were eligible for reduced RT to 30.6 Gy whole ventricular field (WVI) and 54 Gy tumor-bed total dose as compared to 36 Gy CSI and 54 Gy total dose on ACNS0122. An online expert consensus contouring atlas was made available. All RT treatment plans were centrally reviewed for target and normal tissue contours and radiation therapy dose. Brain and spine MRIs of relapsed patients were centrally reviewed. RT doses to areas of recurrence were calculated. Between May 2012 and September 2016, 107 eligible patients were accrued and 66 patients met criteria to proceed to reduced dose and volume RT. Median age was 11 years (range: 4- 22) and 75% were male. 8 of 66 patients progressed. Median follow up for patients without progression was 25 months from RT completion. The 2-year progression-free survival (PFS) was 89% (95% CI: 81%-97%) and overall survival was 92% (95% CI: 86%-99%). After central review, 62 (94%) patients had RT targets and normal structures contoured and dose delivered per protocol; there were 2 major and 2 minor deviations. None of the patients with deviations have progressed. Four (50%) patients had recurrence at end of treatment and median time to progression was 3.5 months (range: 1.7-19.1) from RT start. Importantly, all failures had a distal component, completely out of the RT field. Six patients had spine only progression and 2 had progression in brain and spine. Of those with intracranial relapse, one recurred locally and dose to the area of the recurrence was: V54 = 53%, V30.6 = 100%, mean 52 Gy, maximum 56 Gy, and minimum 31 Gy. The second patient had leptomeningeal relapse and all areas of recurrent disease had received a mean dose of 10 Gy or less. Providing an online contouring atlas can lead to high quality RT targeting and dose delivery on prospective trials. Patterns of failure suggest the spine/thecal sac is at risk for recurrence for localized NGGCT patients who receive WVI plus primary site boost RT after achieving a CR/PR to induction chemotherapy. The early survival data are encouraging, although the distant failure rate remains concerning. Longer follow-up of the ACNS1123 cohort may better inform future recommendations." @default.
• W2898049158 created "2018-10-26" @default.
• W2898049158 creator A5002952095 @default.
• W2898049158 creator A5012736355 @default.
• W2898049158 creator A5020922940 @default.
• W2898049158 creator A5024356241 @default.
• W2898049158 creator A5026088541 @default.
• W2898049158 creator A5039864062 @default.
• W2898049158 creator A5047930377 @default.
• W2898049158 creator A5050235191 @default.
• W2898049158 creator A5056658906 @default.
• W2898049158 creator A5066253784 @default.
• W2898049158 creator A5067969166 @default.
• W2898049158 creator A5068201905 @default.
• W2898049158 creator A5075545081 @default.
• W2898049158 creator A5079087895 @default.
• W2898049158 creator A5079154896 @default.
• W2898049158 creator A5079216912 @default.
• W2898049158 creator A5085032736 @default.
• W2898049158 date "2018-11-01" @default.
• W2898049158 modified "2023-10-04" @default.
• W2898049158 title "A Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT): A Children’s Oncology Group (COG) Study. Patterns of Failure and Radiation Dosimetry for Nongerminomatous Germ Cell Tumors" @default.
• W2898049158 doi "https://doi.org/10.1016/j.ijrobp.2018.06.099" @default.
• W2898049158 hasPublicationYear "2018" @default.
• W2898049158 type Work @default.
• W2898049158 sameAs 2898049158 @default.
• W2898049158 citedByCount "2" @default.
• W2898049158 countsByYear W28980491582020 @default.
• W2898049158 crossrefType "journal-article" @default.
• W2898049158 hasAuthorship W2898049158A5002952095 @default.
• W2898049158 hasAuthorship W2898049158A5012736355 @default.
• W2898049158 hasAuthorship W2898049158A5020922940 @default.
• W2898049158 hasAuthorship W2898049158A5024356241 @default.
• W2898049158 hasAuthorship W2898049158A5026088541 @default.
• W2898049158 hasAuthorship W2898049158A5039864062 @default.
• W2898049158 hasAuthorship W2898049158A5047930377 @default.
• W2898049158 hasAuthorship W2898049158A5050235191 @default.
• W2898049158 hasAuthorship W2898049158A5056658906 @default.
• W2898049158 hasAuthorship W2898049158A5066253784 @default.
• W2898049158 hasAuthorship W2898049158A5067969166 @default.
• W2898049158 hasAuthorship W2898049158A5068201905 @default.
• W2898049158 hasAuthorship W2898049158A5075545081 @default.
• W2898049158 hasAuthorship W2898049158A5079087895 @default.
• W2898049158 hasAuthorship W2898049158A5079154896 @default.
• W2898049158 hasAuthorship W2898049158A5079216912 @default.
• W2898049158 hasAuthorship W2898049158A5085032736 @default.
• W2898049158 hasConcept C126322002 @default.
• W2898049158 hasConcept C141071460 @default.
• W2898049158 hasConcept C143998085 @default.
• W2898049158 hasConcept C154945302 @default.
• W2898049158 hasConcept C2776694085 @default.
• W2898049158 hasConcept C2776938808 @default.
• W2898049158 hasConcept C2777506904 @default.
• W2898049158 hasConcept C2778119113 @default.
• W2898049158 hasConcept C2778239845 @default.
• W2898049158 hasConcept C2781451048 @default.
• W2898049158 hasConcept C2989005 @default.
• W2898049158 hasConcept C31760486 @default.
• W2898049158 hasConcept C41008148 @default.
• W2898049158 hasConcept C4661277 @default.
• W2898049158 hasConcept C509974204 @default.
• W2898049158 hasConcept C71924100 @default.
• W2898049158 hasConceptScore W2898049158C126322002 @default.
• W2898049158 hasConceptScore W2898049158C141071460 @default.
• W2898049158 hasConceptScore W2898049158C143998085 @default.
• W2898049158 hasConceptScore W2898049158C154945302 @default.
• W2898049158 hasConceptScore W2898049158C2776694085 @default.
• W2898049158 hasConceptScore W2898049158C2776938808 @default.
• W2898049158 hasConceptScore W2898049158C2777506904 @default.
• W2898049158 hasConceptScore W2898049158C2778119113 @default.
• W2898049158 hasConceptScore W2898049158C2778239845 @default.
• W2898049158 hasConceptScore W2898049158C2781451048 @default.
• W2898049158 hasConceptScore W2898049158C2989005 @default.
• W2898049158 hasConceptScore W2898049158C31760486 @default.
• W2898049158 hasConceptScore W2898049158C41008148 @default.
• W2898049158 hasConceptScore W2898049158C4661277 @default.
• W2898049158 hasConceptScore W2898049158C509974204 @default.
• W2898049158 hasConceptScore W2898049158C71924100 @default.
• W2898049158 hasIssue "3" @default.
• W2898049158 hasLocation W28980491581 @default.
• W2898049158 hasOpenAccess W2898049158 @default.
• W2898049158 hasPrimaryLocation W28980491581 @default.
• W2898049158 hasRelatedWork W1488648420 @default.
• W2898049158 hasRelatedWork W203516936 @default.
• W2898049158 hasRelatedWork W2073498983 @default.
• W2898049158 hasRelatedWork W2089800013 @default.
• W2898049158 hasRelatedWork W2348495938 @default.
• W2898049158 hasRelatedWork W2789166760 @default.
• W2898049158 hasRelatedWork W2889663263 @default.
• W2898049158 hasRelatedWork W3109167642 @default.
• W2898049158 hasRelatedWork W6933653 @default.
• W2898049158 hasRelatedWork W2133000900 @default.
• W2898049158 hasVolume "102" @default.
• W2898049158 isParatext "false" @default.
• W2898049158 isRetracted "false" @default.
• W2898049158 magId "2898049158" @default.
• W2898049158 workType "article" @default.